1. What Is Integrated Approaches to Testing and Assessment (IATA)?
Integrated Approaches to Testing and Assessment (IATA) are science-based frameworks for combining evidence to answer a specific question about a chemical’s hazards or safety. They integrate existing information, assess its collective strength, and direct additional testing where important uncertainties remain. IATA are flexible assessment approaches, not a single laboratory test or universal checklist.
For chemicals and advanced materials businesses, the executive question is practical: What evidence is sufficient for this decision, and what should we investigate next? Applications include evaluating a replacement additive, resolving a resin ingredient’s data gap, or deciding whether evidence supports advancing a new material. Toxicologists own the scientific conclusions; consultants can connect those conclusions to investment, development governance, and implementation.
2. Origin and Background
Origin: No single creator is established; IATA were documented in Organisation for Economic Co-operation and Development (OECD) guidance by 2014, including guidance for skin corrosion and irritation. Their development reflects collaboration among toxicologists, regulators, and research institutions rather than a single management theorist.
The underlying challenge was to combine diverse evidence—including alternative methods—into scientifically defensible chemical assessments. OECD workshops, reporting guidance, and reviewed case studies helped formalize and disseminate the approach. Its roots remain in chemical safety assessment, even when businesses use its conclusions to inform commercial decisions.
3. How Integrated Approaches to Testing and Assessment (IATA) Works
The core logic is iterative: collect relevant information, evaluate its combined weight, and generate targeted new evidence if the question remains unresolved. Repeat until the evidence supports a conclusion with uncertainty appropriate to the intended decision. Different decisions can require different levels of confidence.
Understanding the acronym
The words in IATA describe its operating logic, not four mandatory sequential stages:
- I — Integrated: Bring relevant evidence together rather than interpreting each result in isolation.
- A — Approaches: Select a combination of methods appropriate to the substance, endpoint, and decision context.
- T — Testing: Generate additional information to address consequential gaps.
- A — Assessment: Interpret the evidence, document uncertainty, and reach a decision-relevant conclusion.
Evidence can include physicochemical properties, human observations, existing animal studies, laboratory assays, computational predictions, and read-across—using justified evidence from related chemicals. Computational models and cell-based tests are inputs, not substitutes for assessing whether the information is relevant and sufficiently reliable.
The useful unit of analysis is usually a substance or material form, an endpoint, and a decision context. For polymers and resins, specify whether the question concerns the polymer, residual monomer, additive, or degradation product. Do not combine these into one assessment without a scientific rationale.
For particle-engineered materials, add size distribution, shape, surface treatment, dissolution, and dispersion behavior to the evidence map. Bulk composition alone is not a sufficient basis for assuming that evidence applies to a particular nanoform.
4. When to Use Integrated Approaches to Testing and Assessment (IATA)
IATA is especially valuable when the decision is precise but the evidence is fragmented. In specialty chemicals, consider it when screening replacement ingredients, planning an endpoint-specific assessment, investigating conflicting supplier studies, or selecting the next study before committing further development resources.
Start with substance identity, composition and impurity information, study reports, model applicability information, and justified analogue evidence. Add use and exposure information when the question concerns risk rather than hazard alone. Product stewardship, toxicology, analytical chemistry, research and development, and manufacturing should contribute relevant expertise.
IATA is less useful when teams ask it to establish that an entire product is “safe” without defining endpoints or uses. Conclusions can also mislead when methods fall outside their applicability domains or evidence cannot be transferred reliably between substances. Scientific credibility does not establish automatic regulatory acceptance across jurisdictions.
Initial scoping can be workshop-led, but total effort depends on study retrieval, material characterization, and laboratory work. A workshop can organize the assessment; it cannot replace it.
5. How to Apply Integrated Approaches to Testing and Assessment (IATA): Step-by-Step
Clarify the decision and scope. State the endpoint, intended use, material form, geography, and decision deadline. Distinguish internal candidate screening from classification, dossier support, or a risk assessment. Agree on what would justify proceeding, stopping, or collecting more evidence.
Gather and qualify the inputs. Retrieve full study reports where possible, not just safety data sheet summaries. Confirm identity, impurities, sample preparation, and study conditions. Record data access rights, provenance, relevance, reliability, and applicability limitations.
Define consistent assessment units. Create separate records for each substance or justified group, material form, and endpoint. Keep differing grades or surface treatments separate unless evidence supports combining them. Identify which production specification the conclusion will cover.
Construct the evidence map. Build a matrix linking evidence sources to the question they address. Include results, method limitations, mechanistic relevance, uncertainty, and gaps. Show the assessment workflow and stopping criteria; avoid an unexplained aggregate “safety score.”
Integrate and challenge the evidence. Have qualified assessors explain agreement and contradiction. Check whether several predictions share the same underlying data. Identify uncertainties that could change the conclusion, rather than treating every missing observation as equally important.
Select targeted follow-up work. Choose studies that address decision-critical gaps. Explain how each possible result would change the assessment. Check the proposed methods against the intended regulatory context before commissioning work.
Translate the conclusion into action. Assign owners for further testing, reformulation, supplier specifications, exposure controls, or dossier updates. Connect the evidence package to health and safety compliance activities without treating a scientific conclusion as automatic permission to launch.
Test sensitivities and establish review triggers. Revisit uncertain analogue choices, composition ranges, exposure assumptions, and conflicting results. Obtain scientific and executive sign-off. Reopen the assessment when suppliers, manufacturing routes, material forms, or intended uses change materially.
Where several candidates remain viable, structured decision-making support can help executives compare development commitments, evidence gaps, and commercial options. Keep business preferences separate from the scientific assessment: a launch deadline must not determine the weight assigned to a study.
6. Example: Integrated Approaches to Testing and Assessment (IATA) in Action
Fictional example: Arden Materials is developing a replacement reactive diluent for an industrial coating resin. Three candidates meet preliminary performance requirements, but their skin-sensitisation evidence differs. Management needs to decide which candidate deserves further development—not authorize immediate commercialization.
The stewardship team defines three candidate–endpoint assessments. Scientists assemble composition data, structural information, relevant analogue studies, and laboratory results. They evaluate whether an appropriate defined approach for skin sensitisation can be applied to each candidate, while documenting method limitations.
Candidate A produces consistent evidence supporting lower sensitisation concern. Candidate B has conflicting results and a solubility problem that undermines interpretation of one assay. Candidate C produces an adverse signal that warrants reconsidering its chemistry.
The team does not average the results into a ranking. It advances A to the next development gate, defers B pending targeted investigation, and sends C back for reformulation. Other hazard endpoints remain open for A.
Procurement establishes impurity specifications consistent with the assessed material. Analytical chemistry confirms that development batches meet those specifications. Stewardship records remaining questions, and the commercial team verifies proposed customer uses. The outcome is a defensible development sequence with clear evidence requirements—not a blanket claim of safety.
7. Strengths and Limitations
Strengths
- Decision focus: Connects testing expenditure to a defined question rather than a habitual study package.
- Evidence reuse: Existing information and justified read-across can reduce unnecessary testing, including animal testing.
- Visible uncertainty: Helps executives distinguish a promising material from one whose assessment remains unresolved.
- Cross-functional clarity: Makes scientific findings easier to translate into specifications, development priorities, and review responsibilities.
Limitations
IATA depends on expert judgment and the quality of its inputs. Its flexibility does not guarantee reproducibility, adequate endpoint coverage, or regulatory acceptance. OECD publication of an illustrative case study does not imply acceptance of that methodology by every member country.
Advanced materials introduce additional challenges: particle behavior and test conditions can affect interpretation, while evidence transfer between forms requires justification.
For management purposes, treat an endpoint-specific conclusion as bounded evidence. It should not become a claim about all hazards, all uses, or overall sustainability.
8. Common Pitfalls and How to Avoid Them
- Assessing the wrong material. Supplier studies may describe a different grade or composition. Confirm that the tested sample represents the specification being evaluated.
- Counting rather than weighing evidence. Several similar predictions can create apparent confidence. Examine their independence, relevance, and shared assumptions.
- Forcing read-across. Structural resemblance alone can become a convenient justification. Require an endpoint-specific hypothesis and investigate differences that could invalidate it.
- Confusing hazard with exposure. Controlled use conditions do not redefine intrinsic hazard. Keep hazard conclusions separate from the subsequent risk assessment.
- Testing without a decision rule. Additional studies can accumulate without resolving the question. Specify beforehand how possible outcomes would alter the conclusion.
- Stopping at the report. A sound assessment can become disconnected from operations. Assign specification owners and change-control triggers before closing the project.
9. How Integrated Approaches to Testing and Assessment (IATA) Relates to Other Frameworks
Adverse Outcome Pathways: organizing biological relevance
An Adverse Outcome Pathway (AOP) links biological events to an adverse effect. Use it before or alongside IATA to clarify what different assays contribute. An AOP organizes mechanistic understanding; IATA evaluates the evidence needed for the particular assessment.
Defined approaches: standardized interpretation
A defined approach specifies information sources and a fixed interpretation procedure. It can operate within IATA or independently where appropriate. Prefer it when it fits the endpoint and applicability domain; use broader IATA when additional evidence or expert interpretation is necessary.
Safe and Sustainable by Design: broadening the decision
Safe and Sustainable by Design (SSbD) considers safety and sustainability throughout a chemical or material’s life cycle. IATA can inform its safety assessment, but does not replace the wider sustainability evaluation. Combine the tools when choosing substitutes so that resolving one hazard concern does not end the design assessment.
10. Key Takeaways
- Start with a specific substance, endpoint, and decision—not a general request to prove safety.
- Integrate existing evidence before commissioning additional studies.
- Investigate uncertainties that could change the decision.
- Characterize the material form and production specification the conclusion covers.
- Separate scientific conclusions, regulatory acceptance, and commercial release decisions.
- Translate the assessment into accountable actions and change-control triggers.
11. FAQs About Integrated Approaches to Testing and Assessment (IATA)
Is IATA an alternative to animal testing?
IATA can reduce animal testing by reusing evidence and integrating non-animal methods. It is not inherently animal-free: existing animal studies, and sometimes additional testing, may form part of an assessment.
Are IATA conclusions automatically accepted by regulators?
No. Acceptance depends on the endpoint, evidence, methods, and regulatory context. An OECD case study illustrates an approach; it does not establish universal acceptance. Confirm the intended authority’s expectations before relying on the assessment for a submission.
Can IATA be applied to nanomaterials?
Yes, but material characterization and evidence transfer require particular attention. Particle size, shape, surface treatment, and behavior can matter; a conclusion for a bulk substance should not automatically be transferred to its nanoforms.
Can smaller chemical companies use IATA?
Yes. Begin with one consequential endpoint and a manageable evidence inventory. Use external toxicology expertise where necessary, retain access to supporting reports, and document uncertainty explicitly. A smaller budget should narrow the assessment’s scope—not lower the scientific standard.
